[¹F]FDG PET/CT Role in Lymphoma

In this book, the potential benefits and limitations of advanced PET/CT techniques and technologies that support novel chemotherapy and radiotherapy approaches in the treatment of lymphoma are described. Particular attention is paid to the major challenge of incorporating progress in quantitative imaging technology, like new imaging variables like Dmax, MTV, TLG, etc.

In the volume, the main evidence about the role of PET/CT in lymphoma, dividing for variants are summarised. The role of 18F-FDG PET/CT in lymphoma is well demonstrated especially in FDG-avid lymphoma (DLBCL, HL, FL), but new findings are emerging about other variants, such as MCL, MALT, Burkitt, etc. Moreover, the technological advancement (new tomographs, new radiotracers, new software) may have a crucial role in the future.

A detailed description of the causes of false-positive, false-negative, and common pitfalls in interpreting the images and the patient preparation for 18F-FDG PET/CT in this setting is given by Authors.

The book, written by international experts about PET/CT role in lymphoma, represents a clear and evidence-based book of interest for all physician dealing with Nuclear Medicine and Hematology/Oncology.

Part I. Introduction. - Lymphoma classification. - PET/CT principles. - PET/CT quantitative biomarkers in lymphoma. - Part II. [18F]FDG PET/CT in Hodgkin Lymphoma. -

Hodgkin Lymphoma. - Part III. [18F]FDG PET/CT in non-Hodgkin Lymphoma. -

Diffuse large B Cell Lymphoma (DLBCL). - Follicular Lymphoma (FL). - Mantle Cell Lymphoma. - T Cell Lymphoma. - Marginal Zone Lymphoma. - Burkitt Lympoma (BL). - Part IV. [18F-FDG] PET/CT Specific Populations. -

Pediatric Population. - An update on [18F-FDG] PET/CT for diagnosing, staging, and guiding therapy in HIV-associated lymphoma. - Lymphoma and [18F]FDG PET/CT in Elderly. - Part V. Future Perspectives. -

New scanners. - Novel radiopharmaceuticals for lymphoma. - Radiomics And Artificial Intelligence.